Monday, October 08, 2018 1:04:25 PM
MCT 465
Alternative Names: MCT-465
Latest Information Update: 28 Sep 2018
At a glance
Originator MultiCell Technologies Inc
Developer MultiCell Technologies Inc; University Health Network
Class Antivirals; RNA
Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Immunostimulants; T lymphocyte stimulants; Toll-like receptor agonists
Orphan Drug Status No
New Molecular Entity Yes
Highest Development Phases
No development reported Cancer; Liver cancer; Viral hepatitis
Discontinued Influenza virus infections
Most Recent Events
28 Sep 2018 No recent reports of development identified for preclinical development in Viral-hepatitis in USA (Parenteral)
04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
04 Nov 2017 No recent reports of development identified for preclinical development in Liver-cancer in USA (Parenteral)
https://adisinsight.springer.com/drugs/800023642
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM